A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL-Reference-Cited by-同舟云学术

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL

Published:2013-10-10 Issue:10 Volume:8 Page:e77155
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Rix Uwe,Colinge Jacques,Blatt Katharina,Gridling Manuela,Remsing Rix Lily L.,Parapatics Katja,Cerny-Reiterer Sabine,Burkard Thomas R.,Jäger Ulrich,Melo Junia V.,Bennett Keiryn L.,Valent Peter,Superti-Furga Giulio

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference53 articles.

1. Chronic myeloid leukemia;CL Sawyers;N Engl J Med,1999

2. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics;R Kurzrock;Ann Intern Med,2003

3. Imatinib as a paradigm of targeted therapies;BJ Druker;Adv Cancer Res,2004

4. Circumventing resistance to kinase-inhibitor therapy;BJ Druker;N Engl J Med,2006

5. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl;E Weisberg;Cancer Cell,2005

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shared and distinct aspects of hematopoietic malignancies such as leukemia and lymphoma;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

2. Tyrosine Kinase Inhibitor Profiling Using Multiple Forskolin-Responsive Reporter Cells;International Journal of Molecular Sciences;2023-09-08

3. A retrospective cytogenetic abnormality in pediatric acute lymphoblastic leukemia: Report of 11 years;Advanced Biomedical Research;2022

4. In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs;Cell;2021-04

5. Acute lymphoid leukemia etiopathogenesis;Molecular Biology Reports;2021-01